As diasialoganglioside GD2-targeting immunotherapies are under clinical and preclinical investigation in NB,25,27, 28, 29 we constructed a GD2-targeted 4-1BB CAR to serve as a positive control for in vitro comparison. The gene discussed is TNFRSF9; the disease is neuroblastoma.